Romania

Show information for:

Information and guides

BackSavedSign in

Support / Info

Clinical trials for melanoma in Romania

Which studies are listed as recruiting, where the centres are, and how to contact the team. Record source: ClinicalTrials.gov.

← All cancer types

How to read this list

Each card is a study listed as recruiting with a recruiting centre in Romania. Open the sections in the card to see the participant overview, study groups, calendar and all published local centres and contacts. The study team confirms eligibility and availability; the original registry record remains available for the complete protocol information.

Trials recruiting now

1 of 3 titles have been rewritten in plain language by our editorial team. The rest still show the registry's protocol wording.

Trials testing a treatment · 3 studies

Something new is being tried here: a medicine, a regimen or a procedure. If you join, you receive either the treatment under study or the standard one, and the team follows you closely.

NCT06112314Phase 3Listed as recruiting

Advanced melanoma, not treated before: a new immunotherapy compared with nivolumab

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.

Minimum age: 18 years

Centres in: Cluj-Napoca · Craiova · Iași

See all centres (3)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06112314. This contact may be in another country; ask which language you can use.

Immunocore Medical Information

844-466-8661 (dialling format unconfirmed)

medical.information@immunocore.com

Immunocore Medical Information EU

+00 800-744-51111 (dialling format unconfirmed)

medinfo.eu@immunocore.com

Source: study registry

Cluj-Napoca

  • L'Institute Oncologique Prof. Dr. Ion Chiricuta (IOCN) (The Oncology Institute Prof. Dr. Ion. Chiricuta)

    Contact for this study

    Source: study registry

Craiova

Iași

  • Victoria Hospital (Centrul de oncologie Euroclinic SRL) (Centrul De Oncologie Medicala) (Euroclinic Onchology Center)

    Contact for this study

    Constantin Volovat, MD

    +40 746 110 096

    cvolovat@gmail.com

    Source: study registry

Who can take part

Advanced melanoma, not treated before: a new immunotherapy compared with nivolumab

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Participants must be HLA-A\*02:01-positive * Participants must have histologically confirmed Stage IV or unresectable Stage III melanoma * Archived or fresh tumor tissue sample that must be confirmed as adequate * Participants must have measurable disease per RECIST 1.1 * Participant must have BRAF V600 mutation status determined * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the study screening date until 5 months after the final dose of study intervention Exclusion Criteria: * Participants with a history of a malignant disease other than those being treated in this study * Participants with untreated, active, or symptomatic central nervous system (CNS) metastases or carcinomatous meningitis * Hypersensitivity to IMC-F106C, nivolumab, relatlimab, or any associated excipients * Participants with clinically significant pulmonary disease or impaired lung function * Participants with clinically significant cardiac disease or impaired cardiac function * Participants with active autoimmune disease requiring immunosuppressive treatment * Participants with any medical condition that is poorly controlled or that would, in the Investigator's or Sponsor's judgment, adversely impact the participant's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results * Participants who received prior systemic anticancer therapy for unresectable or metastatic melanoma * Participants with a history of a life-threatening AE related to prior anti-PD-(L)1 or anti-LAG-3

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Brenetafusp · Nivolumab

  • Group 2 · Studied intervention

    Brenetafusp · Nivolumab

  • Group 3 · Active treatment comparison

    Nivolumab · Nivolumab + Relatlimab

Start of the whole study
5 June 2024
Completion of the whole study
16 October 2027 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Updated in the registry: 25 February 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07221734Phase 3Listed as recruiting

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma

Minimum age: 18 years

Centres in: Craiova

See all centres (1)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07221734. This contact may be in another country; ask which language you can use.

Source: study registry

Craiova

Who can take part

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: 1. Age ≥18 years at the time of signing the informed consent (or adulthood where the legalage of majority in the country is established \>18 years). 2. Body weight ≥50 kg at baseline. 3. Signed informed consent must be obtained before initiation of any study-specific procedures or treatment. 4. ECOG performance status of 0 or 1. 5. Life expectancy for at least 3 months. 6. Untreated, histologically confirmed advanced unresectable Stage III or Stage IV melanoma, as per AJCC 8th Edition staging system. Prior melanoma systemic therapy for earlier stages is allowed for patients who have been disease-free for at least 1 year after end of therapy, except if therapy included use of prohibited medications. Prior use of immune therapies (adjuvant or neoadjuvant) is not allowed as per Exclusion Criteria #2. 7. At least 1 measurable disease lesion by CT or MRI per RECIST v1.1 criteria. 8. Tumour tissue from an unresectable or metastatic site of disease, collected within 90 days prior to randomisation, must be available and provided for PD-L1 testing. All samples must be classified as PD-L1 positive (≥1% to \<5% or ≥5%). If only the old sample \>90 days is available and there is no possibility of having a new biopsy sample, then the subject will be excluded. 9. In the case of prior palliative radiotherapy (on metastatic lesions), this must have been completed at least 2 weeks prior to the study drug administration. No adjuvant radiation therapies are allowed. 10. Any BRAF mutation status is allowed (BRAF-mutated, BRAF wild-type or non-mutated, or BRAF status unknown). 11. Adequate organ function (bone marrow, hepatic, renal, haematologic, endocrine, and coagulation function) should be demonstrated during the screening period. This is defined as: 1. Haematologic function: absolute neutrophil count ≥1.5 × 109/L, platelets 9≥100 × 10 /L, and haemoglobin ≥9 g/dL. \*\* Subjects should not have received RBC transfusion prior to 14 days beforescreening labs. 2. Renal function: serum creatinine level ≤1.5 × ULN or calculated CrCl ≥60 mL/min (using the Cockcroft-Gault formula). 3. Liver function: total bilirubin level ≤1.5 × ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \<3.0 mg/dL), albumin level ≥LLN, AST/ALT ≤2.5 × ULN (≤5 × ULN for subjects with liver metastases). 4. Endocrine function: TSH within normal limits. If TSH is not within normal limits, the subject may still be eligible if T3 and free T4 are within normal limits. 5. Coagulation: INR and aPTT ≤1.5 × ULN unless the subject is receiving anticoagulant therapy. Subjects on anticoagulant therapy must be on a stable anticoagulation regimen and have an INR not above the target therapeutic range for the 14 days preceding the start of the study drug. 12. Female subjects of childbearing potential and their partners, as well as male subjects with female partners of childbearing potential and their partners, must agree to adhere to the use of a highly effective method of contraception during the study and for at least 5 months after the last dose of nivolumab. Refer to Appendix 15.1 for contraception guidance. 13. Non-fertile females can be included. Exclusion Criteria: 1. Subjects receiving any prior systemic therapy for advanced, unresectable, or metastatic Stage III or Stage IV melanoma (except for palliative radiotherapy, in accordance with Inclusion Criteria #9). 2. Subjects receiving any prior immunotherapy (regardless of the melanoma stage), such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-LAG or anti-CTLA-4 therapy (including ipilimumab or any other antibody or drug that specifically targets costimulation of T-cells or immune checkpoints) and/or BRAF-targeted therapy. 3. Participation in another clinical study or treatment with another investigational agent within 4 weeks or 5 elimination half-lives prior to randomisation (whichever is longer) 4. Brain metastases or leptomeningeal metastases. A negative brain imaging of less than 90 days prior to screening is required. 5. Peritoneal melanomatosis. 6. Ocular melanoma, mucosal melanoma and acral lentiginous melanoma. 7. History of another malignancy or a concurrent malignancy. Exceptions include subjects who have been disease-free for 3 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ. 8. Active autoimmune disease that has required systemic treatment in the last 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin or physiological corticosteroid replacement therapy for pituitary or adrenal insufficiency \[daily prednisone at a dose of ≤10 mg or equivalent\]) is not considered a form of systemic treatment. 9. Subjects with hyperthyroidism or hypothyroidism are excluded but those subjects who are stable on hormone replacement will be allowed. 10. Any diagnosis of immunodeficiency, systemic steroid therapy (replacement therapy outlined in Exclusion Criteria #8, inhaled, intranasal, intraocular, or topical steroids are allowed) or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study drug. 11. Any major surgery (eg, hip or spine surgery) less than 28 days prior to the first dose of the study drug. 12. Having received a solid organ/tissue allogeneic or haematopoietic transplant. 13. History and/or current interstitial lung disease or pneumonitis (non-infectious) requiring oral or IV steroids or another immunosuppressive drug. 14. Any active or previous infection requiring therapy (oral or systemic) within 30 days prior to the first dose of the study drug. 15. Have received or are about to receive a live virus vaccination within 30 days prior to the first dose of the study drug. Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted. 16. Known active TB or untreated latent TB. 17. Positive serology for human immunodeficiency virus (HIV 1/2), hepatitis B (HBsAg positive and/or HBcAb positive, and HBV DNA positive, refer to Section 8.3.2.1) or hepatitis C (HCVAb positive and HCV RNA positive). In addition, subjects with untreated positive serology for Strongyloides spp will be excluded. 18. At the time of signing the informed consent, the subject is a regular user (including "recreational use") of any illicit drug or have a recent history (within the past year) of substance abuse (including alcohol). 19. Be pregnant or lactating or expecting to conceive during the study or up to 5 months after the last dose of the study drug. 20. Immediate family member who is at the research site or sponsoring staff who is directlyninvolved in this study. 21. Inability to comply with protocol procedures and/or any other acute or chronic medical condition that may increase the risk for the subject associated with study participation or study drug administration, that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    MB11 (Proposed Nivolumab Biosimilar)

  • Group 2 · Active treatment comparison

    EU-Opdivo®

  • Group 3 · Active treatment comparison

    US- sourced Opdivo®

Start of the whole study
29 December 2025
Completion of the whole study
February 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Full title

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

Updated in the registry: 29 October 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07476326Phase 1Listed as recruiting

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of melanoma.

Minimum age: 18 years

Centres in: Craiova

See all centres (1)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07476326. This contact may be in another country; ask which language you can use.

Dr. Gursharan Singh, MBBS; PhD Pharm Med; LLM-IP

+918028082066

gursharan.singh@biocon.com

Source: study registry

Craiova

Who can take part

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of melanoma.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: 1. Participants greater than or equal to (\>=)18 years of age on the day of signing informed consent (follow local regulatory requirements if the legal age of consent for study participation is \>18 years old). 2. Able to understand and willing to provide consent using the study Informed Consent Form (ICF). The voluntarily signed ICF must be obtained before any study-specific procedures are performed. 3. Histologically or cytologically confirmed Stage IIB, Stage IIC, Stage III, or Stage IV melanoma (per American Joint Committee on Cancer, 8th edition) that was completely surgically resected. Complete surgical resection requires removal of all clinically or radiographically evident regional disease. Completion of lymph node dissection is not required unless clinically indicated. Participants must have been surgically rendered free of disease with negative margins on resected specimens documented by appropriate pathology and surgical reports. 4. Complete surgical resection of melanoma must have been performed within 12 weeks before randomization. 5. All participants must have disease-free status documented by a complete physical examination and imaging studies before randomization. 6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. 7. Participants must have recovered from melanoma related surgery and its complications before randomization, as per investigator. Exclusion Criteria: 1. History of ocular/uveal melanoma. 2. Participants with an active, known, or suspected autoimmune disease are to be excluded from participation. Participants who have received systemic treatment for an autoimmune disease within the past 2 years before randomization (eg, with disease-modifying agents, corticosteroids, or immunosuppressive drugs) are also excluded. 3. History of active malignancy other than melanoma under study within 3 years before randomization, except for locally curable early-stage cancers (carcinoma in situ or Stage I) that have been curatively treated, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast. 4. Participants with a condition requiring systemic treatment with either corticosteroids \>10 mg daily prednisone or equivalent or other immunosuppressive medications within 14 days before randomization. Inhaled or topical steroids, and adrenal replacement steroid doses \<=10 mg daily prednisone or equivalent, are permitted in the absence of active autoimmune disease 5. Female participants who are pregnant or breastfeeding at the screening visit, or who intend to become pregnant or breastfeed at any time during the study and for 150 days after the last dose of study intervention. 6. Use of an investigational agent or an investigational device within 28 days or 5 half-lives (if half-life is known for the investigational agent), whichever is longer, before randomization or have not recovered from AEs associated with such therapies to Grade 1 or below (based on CTCAE Version 6.0). 7. Any antineoplastic therapy after the complete resection of melanoma under study (eg, chemotherapy, radiation therapy, targeted agents, biotherapy, or limb perfusion). 8. Participants who have received a live/attenuated vaccine within 28 days before randomization. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. 9. Expected to receive any other form of antineoplastic therapy during the clinical study. 10. Participants who received previous systemic therapy with any of the following: anti-programmed cell death-protein 1 (PD-1), anti programmed cell death-ligand 1 (PD-L1), anti-programmed cell death-ligand 2 (PD-L2), anti-CD137, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies (including nivolumab or pembrolizumab or ipilimumab or other CTLA-4 targeting agents), chimeric antigen receptor T-cell therapy cells, or any agents targeting the IL-2 pathway or other T-cell co-stimulation/ checkpoint pathways. 11. Treatment with complementary medications (eg, herbal supplements or traditional medicines) with an antineoplastic intent to treat the melanoma within 2 weeks before randomization. Such medications are permitted if they are used as supportive care. 12. Participants will be excluded if clinical assessment or laboratory investigations before randomization demonstrate any of the following: 1. White blood cells: less than (\<) 2000 per microliter 2. Neutrophils: \<1500 per microliter 3. Platelets: \<100 \*103 per microliter 4. Hemoglobin: \<9.0 gram per deciliter (g/dL) 5. Participants with estimated creatinine clearance (CrCl) (measured or calculated) less than or equal to (\<=) 40 milliliter per minute (mL/min). • CrCl: using the Cockroft-Gault formula: * Female CrCl = \[(140 - age in years) \* weight in kilogram (kg) \* 0.85\] divided by (72 \* serum creatinine in milligram per deciliter \[mg/dL\]) * Male CrCl = \[(140 - age in years) \* weight in kg \* 1.00\] divide by (72 \* serum creatinine in mg/dL) 6. Aspartate aminotransferase: greater than (\>) 2.5 \* upper limit of normal (ULN) 7. Alanine aminotransferase: \>2.5 \* ULN 8. Total bilirubin \>1.5 \* ULN (except participants with Gilbert Syndrome who must have a total bilirubin level of \<3.0 \* ULN) 13. Participants positive for human immune deficiency virus (HIV-1 and HIV-2) tests. Screening for HIV infection must adhere to local regulatory guidelines and confirm the absence of HIV-1 and HIV-2 infection. Note: Participants with documented HIV infection may be enrolled where required by local regulatory or ethics committee guidance, provided all the following criteria are met: * The participant is on stable antiretroviral therapy for at least 12 weeks prior to the first dose of study treatment, and no planned change in antiretroviral therapy regimen during the PK sampling period. * Adequate immune function, defined as: CD4+ T cell count greater than or equal to (\>=) 350 cells per millimeter cube (cells/mm\^3) at screening * No history of uncontrolled or recent Acquired Immunodeficiency Syndrome (AIDS) defining illness, that is \[ie\], no active AIDS defining condition within the past 12 months * Undetectable viral RNA load 14. Participants having positive test result for hepatitis B virus (HBV) or hepatitis C virus (HCV) indicating presence of virus, eg, hepatitis B surface antigen (Australia antigen) positive, or hepatitis C antibody (anti- HCV) positive (except if HCV RNA negative). 15. Participants with history or current evidence of any clinically significant medical condition (including but not limited to physical examination, vital signs, electrocardiogram \[ECG\] findings, laboratory results), or ongoing therapy, that could confound study results, increase participation risk, or are deemed not in the participant's best interest by the treating investigator. 16. Known history of allergy or hypersensitivity to IMP components. 17. Known history of severe hypersensitivity reaction (Grade \>=3) to any monoclonal antibody. 18. Participants who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness. 19. Has documented or known current alcohol/drug abuse that precludes the participant's ability to adhere to the protocol. 20. Prisoners or participants who are involuntarily incarcerated.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Bmab1700

  • Group 2 · Studied intervention

    Opdivo

Start of the whole study
9 September 2026
Completion of the whole study
16 February 2028 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Full title

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

Updated in the registry: 6 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

Source: ClinicalTrials.gov, the public registry of the US National Library of Medicine. Data retrieved on 19 Nov 2026.

Worth reading before you talk to your doctor

Material from our library to help you prepare your questions.

Where the official information lives

View the records in the official registries.

Where the data on this page comes from

The counts come from ClinicalTrials.gov and reflect trials marked in the registry as recruiting that also have at least one site in Romania marked as recruiting. We show cities, centre names and contacts when published. General contacts added from the OncoDots directory are labelled separately. A “recruiting” status does not guarantee that a site is still accepting patients on the day you check, because the registry may lag behind the situation at the hospital. For any decision, consult the official record and discuss it with your doctor.